Fidelity SPDR Advertisement
Home > Boards > Free Zone > Big Board Trading - Technical > *SCALPSWINGSTRADDLE* ($$$)

Pharmacyclics pullback a buying opportunity, says Credit Suisse

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
madrose1 Member Profile
Member Level 
Followed By 295
Posts 47,229
Boards Moderated 10
Alias Born 04/07/01
160x600 placeholder
U.S. Stocks: Futures Edge Up Ahead Of Data Deluge
U.S. stock futures made small advances on Wednesday, the last full day of trading ahead of the Thanksgiving break, ahead of a barrage of data on consumer prices, new-home sales and other indicators.
Top Equities Stories Of The Day
Spotify's Revenue Rose in 2013, But Losses Continued - 2nd Update
Telefónica Works to Redraw Its Empire
SEC Grants Bank of America Short-Term Waiver from Hedge-Fund Restrictions
Samsung to Buy Back $2 Billion Worth of Shares -- Update
Appeals Court Grants TV Programmers Stay in FCC Dispute -- Update
Canada Resident Caught Up in China Corruption Probe
Regulators Give Passing Grade to Wells Fargo Plan on Theoretical Bankruptcy -- Update
Correction to La Compagnie Fares Story
madrose1 Member Level  Monday, 03/25/13 08:37:55 AM
Re: None
Post # of 650143 
Pharmacyclics pullback a buying opportunity, says Credit Suisse
Credit Suisse would use the pullback in Pharmacyclics as a buying opportunity given the multi-billion dollar potential of ibrutinib. Shares are Outperform rated with a $90 price target

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist